---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000125"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T12:57:28.102324+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance

## Summary
- VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.
- GAAP net income $107.2M (+91% YoY); Non-GAAP EPS $0.96 (+78% YoY) vs $0.54.
- FY2024 guidance raised: total revenue, Non-GAAP operating margin, Non-GAAP EPS all increased.
- ROCTAVIAN restructuring: focus on US, Germany, Italy; target $60M annual expenses by 2025; Q2 rev $7M.
- Discontinued BMN 293 (gene therapy for hypertrophic cardiomyopathy); BMN 351/349/333 on track.

## SEC filing metadata
- accession: 0001048477-24-000125
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000125/0001048477-24-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000125/bmrn-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000125
- JSON: https://secwatch.observer/filing/0001048477-24-000125.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.